Adcock says CFR buyout officially void; Bayer wins EU nod for birth-control patch; Takeda lures Japanese investors;

@FiercePharma: More than 2,000 Pradaxa patients are suing Boehringer over severe or fatal bleeding. More | Follow @FiercePharma

@TracyStaton: Our best-read feature every year: The most influential people in biopharma today. Report | Follow @TracyStaton

@EricPFierce: It's 1 thing for an API seller to have poor quality controls, but FDA says it's a real problem to have none. Story | Follow @EricPFierce

@CarlyHFierce: Merck consumer-health deal heats up with $10B-plus bids expected soon. News | Follow @CarlyHFierce

> South African drugmaker Adcock Ingram said its agreement with Chile-based CFR Pharmaceuticals to cancel their failed merger agreement is now official. Report

> Bayer won European approval for its new transparent contraceptive patch, which comprises the hormonal drugs gestodene and ethinylestradiol. Report

> Japan's Takeda Pharmaceuticals is the most popular stock in the early days of a new tax-free investment program there. Report

> India's Sun Pharmaceuticals hiked its growth outook after its profits for the fiscal third quarter topped forecast. Report

> Teva Pharmaceutical Industries ($TEVA) said that the FDA granted full approval for its leukemia drug Synribo, which won a conditional OK in 2012. Report

Medical Device News

@FierceMedDev: Illumina's Jay Flatley brought sequencing to another level in 2013--the $1000 genome is now a reality. Report | Follow @FierceMedDev

@MarkHFierce: Amedica's IPO is going steadily. Stock at $6.19 as of 10:56 A.M. Moderately higher. Story | Follow @MarkHFierce

@MichaelGFierce: CalTech engineers have created an antibody carrier that could prevent intravaginal HIV infection. Not a vaccine... More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: "Musical hallucinations" give scientists clues about brain function, hearing loss. Article | Follow @EmilyWFierce

> Teleflex triggered a global recall for a tracheal tube that can crease during use. Story

> Illumina and Yuri Milner will back a genomics startup incubator in San Francisco. More

> Blood Purification Technologies gets FDA green light for artificial kidney trials. News

> Miramar Labs raises $10M to market device that eliminates underarm sweat glands. Item

Biotech News

@FierceBiotech: Like him or not, Myriad Genetics' Peter Meldrum helped make predictive cancer testing viable. Profile | Follow @FierceBiotech

@JohnCFierce: Who's influential in biopharma? (ICYMI) Report | Follow @JohnCFierce

@DamianFierce: FDA rejects Durect's pitch to market post-operative pain therapy. More | Follow @DamianFierce

@EmilyMFierce: GlaxoSmithKline joins $115M antibiotics development initiative. Story via FierceBiotech Research | Follow @EmilyMFierce

> Novartis CEO Jimenez looking for new places to hatchet blockbuster R&D budget. News

> Biotech IPOs roll on with Concert's $84M aria. Article

> FDA panel pillories The Medicines Co.'s clot-fighting cangrelor. More

Pharma Manufacturing News

> Congress wants more info about the quality of foreign-made generics. Story

> 2 Hospira plants improve their FDA standing as improvements kick in. Article

> Irish Regeneron plant to produce tax benefits as well as drugs. Story

> Catalent to expand in U.S. and add 230 jobs to its Kansas City operation. News

> The FDA slams a Hong Kong API for the sorry state of its quality controls. Story

> New plants in Middle East are a testament to the region's emerging market status. Item

Vaccines News

> Quadrivalent flu vaccines drive surge in sales at AstraZeneca, GSK and Sanofi. Earnings

> The President's Cancer Panel is pushing for increased use of Merck's and GSK's HPV vaccines. News

> Crowdfunded HIV project draws criticism from scientists. Story

> CDC: Adult vaccination rates are still well below targets. Article

> The U.S. flu season is slowly winding down after hitting some states hard. Story

> Global measles deaths have dropped 78% since 2000. Brief

And Finally... A new bill proposes to bar FDA scrutiny of "low risk" health IT products, such as electronic health records and fitness apps. Report

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.